Tag: FDA fast track

GE HealthCare Doses First Patient in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent

GE HealthCare has dosed the first patient in its Phase 2/3 LUMINA…

ME Desk

FDA Grants Breakthrough Therapy Designation to Novartis’ Ianalumab for Sjögren’s Disease

The FDA has granted Breakthrough Therapy designation to Novartis’ ianalumab for Sjögren’s…

ME Desk